Effects of 14 frequently used drugs on prostate‑specific antigen expression in prostate cancer LNCaP cells
- Authors:
- Kazuhiro Iguchi
- Maki Hashimoto
- Masafumi Kubota
- Shuji Yamashita
- Mitsuhiro Nakamura
- Shigeyuki Usui
- Tadashi Sugiyama
- Kazuyuki Hirano
View Affiliations
Affiliations: Laboratory of Drug Metabolism and Pharmacokinetics, Gifu Pharmaceutical University, Gifu 501‑1196, Japan, Laboratory of Community Pharmaceutics, Gifu Pharmaceutical University, Gifu 501‑1196, Japan, Laboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, Gifu 501‑1196, Japan, Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu 501‑1196, Japan
- Published online on: March 5, 2014 https://doi.org/10.3892/ol.2014.1936
-
Pages:
1665-1668
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Prostate cancer occurs more frequently among older males and such elderly individuals often have chronic underlying disorders for which various drugs are administered for treatment. The levels of prostate‑specific antigen (PSA), a widely used prostate cancer marker, are influenced by a number of drugs, such as non‑steroidal anti‑inflammatory drugs and statins. In the present study, the drugs prescribed to patients on a repeat prescription collected at the pharmacy of the Gifu Pharmaceutical University (Gifu, Japan) were examined for their effects on the levels of PSA expression in prostate cancer LNCaP cells. Among the 14 drugs investigated, betamethasone, an agonist of the glucocorticoid receptor, was found to increase the levels of PSA mRNA expression in the LNCaP cells. This betamethasone‑induced expression was mediated, at least in part, through androgen receptor (AR) transcriptional activation. Dexamethasone, a typical agonist of the glucocorticoid receptor, was also found to stimulate the AR transcriptional activity, however, to a lesser extent than betamethasone. Therefore, it would be interesting to examine in future studies whether the serum PSA levels in prostate cancer patients are influenced by betamethasone.
View References
|
1
|
Mochtar CA and Andika RS: The value of
prostate-specific antigen in Asia. Ther Adv Urol. 2:77–83. 2010.
View Article : Google Scholar
|
|
2
|
Fowke JH, Motley SS, Barocas DA, et al:
The associations between statin use and prostate cancer screening,
prostate size, high-grade prostatic intraepithelial neoplasia
(PIN), and prostate cancer. Cancer Causes Control. 22:417–426.
2011. View Article : Google Scholar
|
|
3
|
Hamilton RJ, Banez LL, Aronson WJ, et al:
Statin medication use and the risk of biochemical recurrence after
radical prostatectomy: results from the Shared Equal Access
Regional Cancer Hospital (SEARCH) Database. Cancer. 116:3389–3398.
2008. View Article : Google Scholar
|
|
4
|
Murad AS, Down L, Davey Smith G, et al:
Associations of aspirin, nonsteroidal anti-inflammatory drug and
paracetamol use with PSA-detected prostate cancer: findings from a
large, population-based, case-control study (the ProtecT study).
Int J Cancer. 128:1442–1448. 2011. View Article : Google Scholar
|
|
5
|
Chang SL, Harshman LC and Presti JC Jr:
Impact of common medications on serum total prostate-specific
antigen levels: analysis of the National Health and Nutrition
Examination Survey. J Clin Oncol. 28:3951–3957. 2010. View Article : Google Scholar
|
|
6
|
Iguchi K, Toyama T, Ito T, et al:
Antiandrogenic activity of resveratrol analogs in prostate cancer
LNCaP cells. J Andrology. 33:1208–1215. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Iguchi K, Hayakawa Y, Ishii K, et al:
Characterization of the low pH/low nutrient-resistant LNCaP cell
subline LNCaP-F10. Oncol Rep. 28:2009–2015. 2012.PubMed/NCBI
|
|
8
|
Berrevoets CA, Veldscholte J and Mulder E:
Effects of antiandrogens on transformation and transcription
activation of wild-type and mutated (LNCaP) androgen receptors. J
Steroid Biochem Mol Biol. 46:731–736. 1993. View Article : Google Scholar
|
|
9
|
Otsuka T, Iguchi K, Fukami K, et al:
Androgen receptor W741C and T877A mutations in AIDL cells, an
androgen-independent subline of prostate cancer LNCaP cells. Tumour
Biol. 32:1097–1102. 2011. View Article : Google Scholar
|
|
10
|
Chang CY, Walther PJ and McDonnell DP:
Glucocorticoids manifest androgenic activity in a cell line derived
from a metastatic prostate cancer. Cancer Res. 61:8712–8717.
2001.
|
|
11
|
Koochekpour S: Androgen receptor signaling
and mutations in prostate cancer. Asian J Andrology. 12:639–657.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kassi E and Moutsatsou P: Glucocorticoid
receptor signaling and prostate cancer. Cancer Lett. 302:1–10.
2011. View Article : Google Scholar : PubMed/NCBI
|
